In one of the studies, combining trametinib with the new SOS1-KRAS interaction inhibitor BI-3406, which targets the catalytic region of SOS1, makes KRAS-driven tumours more susceptible to MEK inhibition in mice models [111]. Here, MAP2K7 is linked to neoplasm.